Advantage Alpha Capital Partners LP Grows Position in Omnicell, Inc. (NASDAQ:OMCL)

Advantage Alpha Capital Partners LP increased its holdings in Omnicell, Inc. (NASDAQ:OMCL) by 14.9% in the 4th quarter, HoldingsChannel.com reports. The fund owned 52,041 shares of the company’s stock after buying an additional 6,753 shares during the period. Advantage Alpha Capital Partners LP’s holdings in Omnicell were worth $2,317,000 as of its most recent filing with the Securities & Exchange Commission.

Several other large investors have also recently made changes to their positions in OMCL. Smartleaf Asset Management LLC lifted its holdings in Omnicell by 51.5% during the fourth quarter. Smartleaf Asset Management LLC now owns 803 shares of the company’s stock valued at $35,000 after purchasing an additional 273 shares during the last quarter. Van ECK Associates Corp grew its holdings in shares of Omnicell by 47.0% during the fourth quarter. Van ECK Associates Corp now owns 985 shares of the company’s stock worth $44,000 after purchasing an additional 315 shares in the last quarter. First Horizon Advisors Inc. lifted its holdings in shares of Omnicell by 36.3% during the 4th quarter. First Horizon Advisors Inc. now owns 1,333 shares of the company’s stock worth $59,000 after acquiring an additional 355 shares during the last quarter. KBC Group NV boosted its holdings in shares of Omnicell by 60.8% in the 4th quarter. KBC Group NV now owns 2,057 shares of the company’s stock worth $92,000 after purchasing an additional 778 shares in the last quarter. Finally, AlphaQuest LLC lifted its holdings in shares of Omnicell by 307.8% in the 4th quarter. AlphaQuest LLC now owns 3,576 shares of the company’s stock worth $159,000 after acquiring an additional 2,699 shares during the last quarter. 97.70% of the stock is owned by hedge funds and other institutional investors.

Omnicell Trading Down 2.7 %

NASDAQ OMCL opened at $33.94 on Monday. The company has a market capitalization of $1.59 billion, a price-to-earnings ratio of 125.71, a price-to-earnings-growth ratio of 7.53 and a beta of 0.85. Omnicell, Inc. has a one year low of $25.12 and a one year high of $55.75. The company has a debt-to-equity ratio of 0.13, a quick ratio of 1.22 and a current ratio of 1.37. The company’s 50-day simple moving average is $39.77 and its two-hundred day simple moving average is $42.90.

Omnicell (NASDAQ:OMCL) last posted its quarterly earnings data on Thursday, February 6th. The company reported $0.45 earnings per share for the quarter, missing analysts’ consensus estimates of $0.57 by ($0.12). Omnicell had a return on equity of 3.82% and a net margin of 1.13%. Equities analysts forecast that Omnicell, Inc. will post 1.09 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of research firms recently commented on OMCL. JPMorgan Chase & Co. lowered their price target on shares of Omnicell from $44.00 to $36.00 and set a “neutral” rating for the company in a report on Thursday. Wells Fargo & Company dropped their price objective on shares of Omnicell from $49.00 to $40.00 and set an “equal weight” rating on the stock in a research note on Monday, January 13th. Benchmark reiterated a “buy” rating and set a $62.00 target price on shares of Omnicell in a research note on Tuesday, February 4th. StockNews.com upgraded shares of Omnicell from a “hold” rating to a “buy” rating in a research note on Thursday, March 6th. Finally, Bank of America decreased their price target on shares of Omnicell from $54.00 to $46.00 and set a “neutral” rating on the stock in a research report on Monday, January 6th. Four investment analysts have rated the stock with a hold rating and three have given a buy rating to the company’s stock. According to data from MarketBeat, the stock has a consensus rating of “Hold” and a consensus target price of $51.00.

Omnicell Company Profile

Omnicell, Inc, together with its subsidiaries, provides medication management solutions and adherence tools for healthcare systems and pharmacies the United States and internationally. The company offers point of care automation solutions to improve clinician workflows in patient care areas of the healthcare system; XT Series automated dispensing systems for medications and supplies used in nursing units and other clinical areas of the hospital, as well as specialized automated dispensing systems for operating room; and robotic dispensing systems for handling the stocking and retrieval of boxed medications.